A selective
catechol-O-methyltransferase inhibitor,
OR-462, was studied for its ability to affect pharmacokinetic properties of
L-dopa after the p.o. administration of the inhibitor to rats and mice. When
OR-462 was given to rats at the dose range of 0.3 to 30 mg/kg in conjunction with
L-dopa and
carbidopa, a dose-related and long-lasting (greater than 5 hr) increase in striatal
L-dopa and
dopamine levels as well as a reduction in
3-O-methyldopa levels were shown. For a 50% reduction of the
3-O-methyldopa levels a dose of 6 mg/kg of
OR-462 was needed. The increase in striatal
homovanillic acid, an O-methylated metabolite of
dopamine which poorly penetrates the blood brain barrier, indicates that O-methylation was not inhibited in the brain. In order to get the same
dopamine levels in striatum the
L-dopa dose could be lowered to one-fourth when
OR-462 was added. The
L-dopa-sparing effect of
OR-462 given p.o. was also demonstrated in two behavioral parkinsonian models.
OR-462 given at doses of 3 to 30 mg/kg in conjunction with
L-dopa and
carbidopa, dose-dependently potentiated the
L-dopa-induced reversal of hypoactivity in reserpinized mice. Likewise, the same doses of
OR-462 caused a marked potentiation of
L-dopa-induced contralateral turning behavior in rats with unilateral nigrostriatal lesions produced by
6-hydroxydopamine. The data suggest a possible beneficial effect of
OR-462 in the
therapy of
Parkinson's disease.